Results 11 to 20 of about 3,395 (155)

Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat

Frontiers in Cardiovascular Medicine, 2022
AimsThe efficacy of anti-proprotein convertase subtilisin/Kexin type 9 (PCSK9) monoclonal antibodies in patients with atherosclerotic cardiovascular disease (ASCVD) remains unclear.
Hong-Fei Wang, Hong-Fei Wang, Yu-Cheng Mao, Yu-Cheng Mao, Xin-Yi Xu, Xin-Yi Xu, Si-Yu Zhao, Si-Yu Zhao, Dan-Dan Han, Dan-Dan Han, Shi-Yao Ge, Shi-Yao Ge, Kai Song, Kai Song, Chang Geng, Chang Geng, Qing-Bao Tian, Qing-Bao Tian   +17 more
doaj   +1 more source

Glycaemic effects of non-statin lipid-lowering therapies [PDF]

, 2016
Since the publication of the JUPITER trial, attention has been focused on the adverse glycemic effects of statin therapy. Although the modest increase in the risk of new diabetes mellitus is outweighed by the reduction in cardiovascular events for ...
Collins, Patrick D., Sattar, Naveed
core   +3 more sources

Alirocumab effect on preventing periprocedural ischaemic events in coronary heart disease patients undergoing coronary stenting (APPEASE trial): study protocol of a multicentre, open-label, randomised controlled trial

BMJ Open, 2023
Introduction Percutaneous coronary intervention (PCI)-related myocardial infarction (type 4a MI) and major periprocedural myocardial injury have been demonstrated leading to poor prognosis of patients with coronary heart disease (CHD) undergoing elective
Yang Chen, Suhua Li, Lianxiong Yuan, Zhenyu Xiong, Jinlai Liu, Xiaoxian Qian, Longgen Xiong, Leile Tang, Zhuoshan Huang, Xiaodong Zhuang, Shaozhao Zhang, Yiquan Huang, Aiwen Lin, Odong Christopher, Bingyuan Wu, Yesheng Ling, Qiang Jie, Xinxue Liao   +17 more
doaj   +1 more source

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol

Cardiovascular Diabetology, 2020
Background Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk.
Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller-Wieland, Bertrand Cariou, Kausik K. Ray, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Marc Israel, Rita Samuel, Stefano Del Prato   +10 more
doaj   +1 more source

Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

Frontiers in Cardiovascular Medicine, 2023
BackgroundDespite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals.
Maciej Banach, Maciej Banach, Maciej Banach, Maciej Banach, Joanna Lewek, Joanna Lewek, Kaja Pol, Daniel Rabczenko, Serban M. Balanescu, Vladimir Blaha, Richard Ceska, Piotr Jankowski, Piotr Jankowski, Stanisław Surma, Genovefa Kolovou, Evangelos Liberopoulos, Florin Mitu, Magda Mitu, Franjo Husam Naji, Gyorgy Paragh, Magdalena Popławska, Michal Vrablik, Daniel Pella   +22 more
doaj   +1 more source

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: the role of PCSK9 inhibitors [PDF]

, 2017
Familial hypercholesterolaemia is an autosomal dominant inherited disorder characterised by elevated low-density lipoprotein cholesterol levels and consequently an increased risk of atherosclerotic cardiovascular disease (ASCVD).
Ceska R, Ceska R, De Castro-Orós I, Kastelein JJ, Lloyd-Jones DM, Pecin I, Strat AL, Yudi M   +7 more
core   +5 more sources

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundAlirocumab undergoes target‐mediated clearance via binding of proprotein convertase subtilisin/kexin type 9 (PCSK9). Statins increase PCSK9 levels; the effects of nonstatin lipid‐lowering therapies are unclear.
Jacques Rey, Franck Poitiers, Tobias Paehler, Aurélie Brunet, A. Thomas DiCioccio, Christopher P. Cannon, Howard K. Surks, Jean‐Louis Pinquier, Corinne Hanotin, William J. Sasiela   +9 more
doaj   +1 more source

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. [PDF]

, 2018
AimsThis analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials.Materials and methodsData ...
Bujas-Bobanovic, Maja, Ginsberg, Henry N, Henry, Robert R, Letierce, Alexia, Louie, Michael J, Müller-Wieland, Dirk, Taub, Pam R   +6 more
core   +1 more source

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]

Journal of Lipid Research, 2014
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition is a potential novel strategy for treatment of CVD. Alirocumab is a fully human PCSK9 monoclonal antibody in phase 3 clinical development.
Susan Kühnast, José W.A. van der Hoorn, Elsbet J. Pieterman, Anita M. van den Hoek, William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-Ludwig Schäfer, Uwe Schwahn, J. Wouter Jukema, Hans M.G. Princen   +10 more
doaj   +1 more source

Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism [PDF]

, 2017
No abstract ...
Packard, Chris J.
core   +1 more source